Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting

AIMS: There is a paucity of comparative data on the use of sorafenib and lenvatinib for unresectable hepatocellular carcinoma. We assessed the real‐world treatment outcomes between using sorafenib and lenvatinib for unresectable hepatocellular carcinoma in the multiple molecular‐targeted therapy era...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Taito, Morimoto, Manabu, Ueno, Makoto, Kubota, Kousuke, Uojima, Haruki, Hidaka, Hisashi, Chuma, Makoto, Numata, Kazushi, Tsuruya, Kota, Hirose, Shunji, Kagawa, Tatehiro, Hattori, Nobuhiro, Watanabe, Tsunamasa, Matsunaga, Kotaro, Yamamoto, Kouji, Tanaka, Katsuaki, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762625/
https://www.ncbi.nlm.nih.gov/pubmed/35071785
http://dx.doi.org/10.1002/jgh3.12691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762625/
https://www.ncbi.nlm.nih.gov/pubmed/35071785
http://dx.doi.org/10.1002/jgh3.12691

Ejemplares similares